GlassScriptPhysician profile
Bradley J Smith
NPI 1902928047
$4,677.88
in general payments reported to CMS, 2019-2025
24 companies · $627 in 2025
The $627 reported for 2025 was more than what 85% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $817 · 2021: $2,119 · 2022: $411 · 2023: $127 · 2024: $192 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.24 |
| Education | $156.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pylant Medical | $1,795.43 | 2020-2021 | |
| Arthrex, INC. | $693.00 | 2021 | |
| Novo Nordisk INC | $442.61 | 2019-2023 | Ozempic, Rybelsus |
| Ferring Pharmaceuticals INC. | $332.94 | 2019-2025 | Euflexxa |
| Amgen INC. | $252.36 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $190.65 | 2019-2025 | Gel-One Cross-Linked Hyaluronate |
| Fidia Pharma USA INC. | $178.46 | 2025 | Hymovis, Richplat Ortho Prp System |
| Kowa Pharmaceuticals America, INC. | $120.32 | 2020-2022 | |
| Bioventus LLC | $112.64 | 2019-2025 | Xcell, Durolane |
| Astellas Pharma US INC | $112.21 | 2024 | Veozah |
| Stryker Corporation | $99.26 | 2022 | |
| Merck Sharp & Dohme LLC | $55.88 | 2025 | Rotateq, Vaxneuvance, Enflonsia |
| Sanofi Pasteur INC. | $31.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.32 | 2019-2022 | |
| Depuy Synthes Sales INC. | $29.31 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.01 | 2021-2022 | |
| Amarin Pharma, INC. | $27.77 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $24.98 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.17 | 2019 | |
| Medtronic, INC. | $23.90 | 2024 | Plasmablade(Tm) |
| Lilly USA, LLC | $20.92 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $19.84 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.72 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.